Table 2.
Cytological diagnosis for women screened after invitation and women undergoing routine or sporadic opportunistic testing
| Screened after invitation1 | Routine opportunistic testing2 | Sporadic opportunistic testing3 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 514,833 (71.2 %) | n = 149,778 (20.7 %) | n = 58,590 (8.1 %) | ||||||||
| n | % | n | % | PPD % (95 % CI)4 | PPR (95 % CI)5 | n | % | PPD % (95 % CI)6 | PPR (95 % CI)7 | |
| Cytological diagnosis | ||||||||||
| Normal cells | 478,855 | (93.0) | 136,797 | (91.3) | −1.7 (−1.87; −1.52) | 0.98 (0.98;0.98) | 53,866 | (91.9) | −1.1 (−1.34; −0.86) | 0.99 (0.99;0.99) |
| ASCUS | 10,868 | (2.1) | 3,674 | (2.5) | 0.4 (−0.17; 0.95) | 1.16 (1.12;1.21) | 1,361 | (2.3) | 0.2 (−0.64;1.04) | 1.10 (1.04;1.16) |
| ASC-H | 2,175 | (0.4) | 846 | (0.6) | 0.2 (−0.38; 0.78) | 1.34 (1.24;1.45) | 250 | (0.4) | 0.0 (−0.83; 0.83) | 1.01 (0.89;1.15) |
| AGC | 634 | (0.1) | 236 | (0.2) | 0.1 (−0.52; 0.72) | 1.28 (1.10;1.49) | 99 | (0.2) | 0.1 (−0.81; 1.01) | 1.37 (1.11;1.70) |
| LSIL | 7,857 | (1.5) | 2,760 | (1.8) | 0.3 (−0.26; 0.86) | 1.21 (1.16;1.26) | 945 | (1.6) | 0.1 (−0.74; 0.94) | 1.06 (0.99;1.13) |
| HSIL | 4,791 | (0.9) | 2,228 | (1.5) | 0.6 (0.03; 1.17) | 1.60 (1.52;1.68) | 408 | (0.7) | −0.2 (−1.05; 0.65) | 0.75 (0.68;0.83) |
| Carcinoma in situ + AIS | 106 | (0.02) | 45 | (0.03) | 0.01 (−0.56; 0.58) | 1.46 (1.00;2.07) | 14 | (0.02) | 0.0 (−0.79; 0.79) | 1.16 (0.66;2.03) |
| Carcinoma8 | 42 | (0.01) | 42 | (0.03) | 0.02 (−0.58; 0.62) | 3.44 (2.24;5.27) | 2 | (0.0) | −0.01 (−0.31; 0.29) | 0.42 (0.10;1.72) |
| Inadequate cervical cytology9 | 9,109 | (1.8) | 2,988 | (2.0) | 0.2 (−0.37; 0.77) | 1.13 (1.08;1.17) | 1,538 | (2.6) | 0.8 (−0.04; 1.64) | 1.48 (1.40;1.56) |
| Others10 | 29 | (0.01) | 8 | (0.01) | 0.0 (−0.78; 0.78) | 0.95 (0.43;2.07) | 1 | (0.0) | NA | NA |
Numbers and proportion vary because of missing data.
ASCUS: atypical squamous cells of undetermined significance; ASC-H: atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (HSIL); AGC: atypical glandular cells; LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; AIS: adenocarcinoma in situ. NA: Not available due to limited data;
Statically significant results are shown in bold.
1) Cervical cytology obtained within 270 days after latest invitation.
2) Cervical cytology obtained between 271 days to 3 years after latest invitation or 2.5 to 3 years after latest cervical cytology.
3) Cervical cytology obtained less than 2.5 years after latest cervical cytology.
4) Prevalence proportion difference (%) for “routine opportunistic testing” compared to “screened after invitation”.
5) Prevalence proportion ratio for “routine opportunistic testing” compared to “screened after invitation”.
6) Prevalence proportion difference (%) for “sporadic opportunistic testing” compared to “screened after invitation”.
7) Prevalence proportion ratio for “sporadic opportunistic testing” compared to “screened after invitation”.
8) Carcinoma including squamous and carcinoma adenocarcinoma.
9) Not suitable for diagnosis
10) Necrosis